Antiblastic  	Antiblastic  	 JJ	B-NP
treatment 	treatment 	 NN	I-NP
,  	,  	 ,	O
for  	for  	 IN	O
solid  	solid  	 JJ	O
tumors 	tumors 	 NNS	O
,  	,  	 ,	O
during  	during  	 IN	O
pregnancy 	pregnancy 	 NN	O
:  	:  	 :	O
a  	a  	 DT	O
crucial  	crucial  	 JJ	O
decision  	decision  	 NN	B-NP
Cancer  	Cancer  	 NNP	I-NP
is  	is  	 VBZ	O
the  	the  	 DT	O
second  	second  	 JJ	O
leading  	leading  	 JJ	O
cause  	cause  	 NN	O
of  	of  	 IN	O
death  	death  	 NN	O
during  	during  	 IN	O
the  	the  	 DT	O
reproductive  	reproductive  	 JJ	B-NP
years  	years  	 NNS	I-NP
complicating  	complicating  	 VBN	O
between  	between  	 IN	O
0.02  	0.02  	 CD	O
percent  	percent  	 NN	O
and  	and  	 CC	O
0.1  	0.1  	 CD	O
percent  	percent  	 NN	O
of  	of  	 IN	O
pregnancies 	pregnancies 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
incidence  	incidence  	 NN	O
is  	is  	 VBZ	O
expected  	expected  	 VBN	O
to  	to  	 TO	O
rise  	rise  	 VB	O
with  	with  	 IN	O
the  	the  	 DT	O
increase  	increase  	 NN	O
in  	in  	 IN	O
age  	age  	 NN	O
of  	of  	 IN	O
childbearing 	childbearing 	 NN	B-NP
.  	.  	 .	O
The  	The  	 DT	O
most  	most  	 RBS	O
common  	common  	 JJ	O
types  	types  	 NNS	O
of  	of  	 IN	O
pregnancy-associated  	pregnancy-associated  	 JJ	O
cancers  	cancers  	 NNS	O
are 	are 	 VBP	O
:  	:  	 :	O
cervical  	cervical  	 JJ	B-NP
cancer 	cancer 	 NN	I-NP
,  	,  	 ,	O
breast  	breast  	 JJ	O
cancer 	cancer 	 NN	O
,  	,  	 ,	O
malignant  	malignant  	 JJ	O
melanoma 	melanoma 	 NN	B-NP
,  	,  	 ,	O
Hodgkin 	Hodgkin 	 NNP	O
's  	's  	 POS	O
lymphoma 	lymphoma 	 NN	B-NP
,  	,  	 ,	O
non-Hodgkin 	non-Hodgkin 	 NNP	O
's  	's  	 POS	O
lymphoma  	lymphoma  	 NN	B-NP
and  	and  	 CC	O
ovarian  	ovarian  	 JJ	B-NP
cancer 	cancer 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
relatively  	relatively  	 RB	O
rare  	rare  	 JJ	O
occurrence  	occurrence  	 NN	O
of  	of  	 IN	O
pregnancy-associated  	pregnancy-associated  	 JJ	O
cancer  	cancer  	 NN	O
precludes  	precludes  	 VBZ	O
conducting  	conducting  	 VBG	O
large 	large 	 JJ	O
,  	,  	 ,	O
prospective  	prospective  	 JJ	B-NP
studies  	studies  	 NNS	I-NP
to  	to  	 TO	O
examine  	examine  	 VB	O
diagnostic 	diagnostic 	 JJ	B-NP
,  	,  	 ,	O
management  	management  	 NN	O
and  	and  	 CC	O
outcome  	outcome  	 NN	B-NP
issues 	issues 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
pregnancy-associated  	pregnancy-associated  	 JJ	O
cancer  	cancer  	 NN	O
is  	is  	 VBZ	O
complex  	complex  	 JJ	O
since  	since  	 IN	O
it  	it  	 PRP	O
may  	may  	 MD	O
be  	be  	 VB	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
adverse  	adverse  	 JJ	O
fatal  	fatal  	 JJ	B-NP
effects 	effects 	 NNS	I-NP
.  	.  	 .	O
In  	In  	 IN	O
pregnant  	pregnant  	 JJ	O
patients  	patients  	 NNS	O
diagnosed  	diagnosed  	 VBN	O
with  	with  	 IN	O
cancer  	cancer  	 NN	O
during  	during  	 IN	O
the  	the  	 DT	O
first  	first  	 JJ	O
trimester 	trimester 	 NN	B-NP
,  	,  	 ,	O
treatment  	treatment  	 NN	O
with  	with  	 IN	O
multidrug  	multidrug  	 JJ	B-NP
anti-cancer  	anti-cancer  	 JJ	I-NP
chemotherapy  	chemotherapy  	 NN	I-NP
is  	is  	 VBZ	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
an  	an  	 DT	O
increased  	increased  	 JJ	O
risk  	risk  	 NN	O
of  	of  	 IN	O
congenital  	congenital  	 JJ	B-NP
malformations 	malformations 	 NN	I-NP
,  	,  	 ,	O
spontaneous  	spontaneous  	 JJ	B-NP
abortions  	abortions  	 NNS	I-NP
or  	or  	 CC	O
fetal  	fetal  	 JJ	B-NP
death 	death 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
therefore 	therefore 	 RB	O
,  	,  	 ,	O
should  	should  	 MD	O
follow  	follow  	 VB	O
a  	a  	 DT	O
strong  	strong  	 JJ	O
recommendation  	recommendation  	 NN	B-NP
for  	for  	 IN	I-NP
pregnancy  	pregnancy  	 NN	I-NP
termination 	termination 	 NN	I-NP
.  	.  	 .	O
Second  	Second  	 JJ	O
and  	and  	 CC	O
third  	third  	 JJ	O
trimester  	trimester  	 JJ	B-NP
exposure  	exposure  	 NN	I-NP
is  	is  	 VBZ	O
not  	not  	 RB	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
teratogenic  	teratogenic  	 JJ	B-NP
effect  	effect  	 NN	I-NP
but  	but  	 CC	O
increases  	increases  	 VBZ	O
the  	the  	 DT	O
risk  	risk  	 NN	O
of  	of  	 IN	O
intrauterine  	intrauterine  	 JJ	B-NP
growth  	growth  	 NN	I-NP
retardation  	retardation  	 NN	I-NP
and  	and  	 CC	O
low  	low  	 JJ	O
birth  	birth  	 NN	B-NP
weight 	weight 	 NN	I-NP
.  	.  	 .	O
There  	There  	 EX	O
are  	are  	 VBP	O
no  	no  	 DT	O
sufficient  	sufficient  	 JJ	O
data  	data  	 NNS	O
regarding  	regarding  	 VBG	O
the  	the  	 DT	O
teratogenicity  	teratogenicity  	 NN	B-NP
of  	of  	 IN	O
most  	most  	 RBS	O
cytotoxic  	cytotoxic  	 JJ	B-NP
drugs 	drugs 	 NNS	I-NP
.  	.  	 .	O
Almost  	Almost  	 RB	O
all  	all  	 DT	O
chemotherapeutic  	chemotherapeutic  	 JJ	B-NP
agents  	agents  	 NNS	I-NP
were  	were  	 VBD	O
found  	found  	 VBN	O
to  	to  	 TO	O
be  	be  	 VB	O
teratogenic  	teratogenic  	 VBN	O
in  	in  	 IN	O
animals  	animals  	 NNS	O
and  	and  	 CC	O
for  	for  	 IN	O
some  	some  	 DT	O
drugs  	drugs  	 NNS	O
only  	only  	 RB	O
experimental  	experimental  	 JJ	B-NP
data  	data  	 NNS	I-NP
exist 	exist 	 VBP	O
.  	.  	 .	O
Moreover 	Moreover 	 RB	O
,  	,  	 ,	O
no  	no  	 DT	O
pharmacokinetic  	pharmacokinetic  	 JJ	B-NP
studies  	studies  	 NNS	I-NP
have  	have  	 VBP	O
been  	been  	 VBN	O
conducted  	conducted  	 VBN	O
in  	in  	 IN	O
pregnant  	pregnant  	 JJ	O
women  	women  	 NNS	O
receiving  	receiving  	 VBG	B-NP
chemotherapy  	chemotherapy  	 NN	I-NP
in  	in  	 IN	O
order  	order  	 NN	O
to  	to  	 TO	O
understand  	understand  	 VB	O
whether  	whether  	 IN	O
pregnant  	pregnant  	 JJ	O
women  	women  	 NNS	O
should  	should  	 MD	O
be  	be  	 VB	O
treated  	treated  	 VBN	O
with  	with  	 IN	O
different  	different  	 JJ	O
doses  	doses  	 NNS	O
of  	of  	 IN	O
chemotherapy 	chemotherapy 	 NN	O
.  	.  	 .	O
This  	This  	 DT	O
article  	article  	 NN	O
reviews  	reviews  	 VBZ	O
the  	the  	 DT	O
available  	available  	 JJ	O
data  	data  	 NNS	O
regarding  	regarding  	 VBG	O
the  	the  	 DT	O
different  	different  	 JJ	O
aspects  	aspects  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
cancer  	cancer  	 NN	O
during  	during  	 IN	O
pregnancy 	pregnancy 	 NN	O
.  	.  	 .	O
